PRODUCTS
SERVICES
COMPANY
CONTACT
FAQ
Search
Dictionary
Mobile
Login
Login/Nickname:
Password:
Remember login
Login
Send password reminder...
Jean-Louis Chiasson Selected Research
Type 2 Diabetes Mellitus (MODY)
05/2007
Tumor necrosis factor alpha -238G>A genotype alters postprandial plasma levels of free fatty acids in obese individuals with type 2 diabetes mellitus.
04/2007
Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
07/2006
Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
01/2006
Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.
04/2005
Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
03/2005
The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
10/2004
Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy.
07/2003
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
06/2002
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Articles by Research Topic
Disease
9
Type 2 Diabetes Mellitus (MODY)
05/2007 - 06/2002
3
Cardiovascular Diseases (Cardiovascular Disease)
01/2006 - 07/2003
2
Hypertension (High Blood Pressure)
01/2006 - 07/2003
1
Cystic Fibrosis (Mucoviscidosis)
11/2007
1
Myocardial Infarction
10/2004
Drug/Important Bio-Agent (IBA)
8
Glucose (Dextrose)
FDA Link
Generic
11/2007 - 07/2003
5
Acarbose
FDA Link
Generic
01/2006 - 06/2002
1
Nonesterified Fatty Acids (NEFA)
IBA
05/2007
1
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
IBA
05/2007
1
PPAR alpha
IBA
04/2007
1
Adiponectin
IBA
03/2005